Genmab A/S (GMAB)

Nasdaq · Healthcare · Biotechnology
$50.60-1.46%As of 2026-11-22 · USD
Last session low $50.24Last session high $51.72
52-week low $23.6252-week high $59.97
Market cap
$31.20B
Sector
Healthcare
P/E (TTM)
43.2x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)55.8In the neutral range (30 to 70)
MACD (12, 26, 9)2.39Below its signal line (3.35); histogram -0.96
Bollinger %B (20, 2)34%Inside the bands (46.02 to 59.54)
SMA 2052.78Price is 4.1% below
SMA 5042.99Price is 17.7% above
SMA 20032.01Price is 58.1% above
ATR (20)3.85% of priceAverage true range per day
52-week position74%In the upper part of the 23.62 to 59.97 range

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Latest fiscal yearEnded 2025-12-31: revenue of $3.72B and an operating margin of 33.6%.

Also listed as GMAB.CO (Copenhagen)

More in Biotechnology